Publications by authors named "David Calligaro"

Claim this Profile
C
Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.
Syed Z Imam, Zhen He, Elvis Cuevas, Hector Rosas-Hernandez, Susan M Lantz, David Calligaro

Exp Biol Med (Maywood)· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward.
Ruth A Roberts, Michael Aschner, David Calligaro, Tomas R Guilarte, Joseph P Hanig

Toxicol Sci· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
Patrick C May, Brian A Willis, Stephen L Lowe, Robert A Dean, Scott A Monk, David O Calligaro

J Neurosci· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography.
Rebecca A Wright, Bryan G Johnson, Ce Zhang, Craig Salhoff, Ann E Kingston, David O Calligaro

Neuropharmacology· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
Himanshu P Upadhyaya, Durisala Desaiah, Kory J Schuh, Frank P Bymaster, Mary J Kallman, David O Calligaro

Psychopharmacology (Berl)· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
Patrick C May, Robert A Dean, Stephen L Lowe, Ferenc Martenyi, Scott M Sheehan, David O Calligaro

J Neurosci· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan.
David L Nelson, Lee A Phebus, Kirk W Johnson, David B Wainscott, Marlene L Cohen, David O Calligaro

Cephalalgia· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Joseph H Krushinski, John M Schaus, Dennis C Thompson, David O Calligaro, David L Nelson

Bioorg Med Chem Lett· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro

J Pharmacol Exp Ther· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
Brianne Weiss, Andrew Alt, Ann Marie Ogden, Mary Gates, Donna K Dieckman, David O Calligaro

J Pharmacol Exp Ther· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.
Andrew Alt, Brianne Weiss, Ann Marie Ogden, Xia Li, Scott D Gleason, David O Calligaro

Psychopharmacology (Berl)· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Kurt Rasmussen, Mark J Benvenga, Frank P Bymaster, David O Calligaro, Ilene R Cohen

J Pharmacol Exp Ther· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor.
George H Searfoss, William H Jordan, David O Calligaro, Elizabeth J Galbreath, Linda M Schirtzinger

J Biol Chem· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muscarinic mechanisms of antipsychotic atypicality.
Frank P Bymaster, Christian C Felder, Eleni Tzavara, George G Nomikos, David O Calligaro

Prog Neuropsychopharmacol Biol Psychiatry· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis